Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review

B. Jayakrishnan*, Mansour Al-Moundhri, Ikram Burney, Zamzam Al-Hashami, Khalid Al-Bimani

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةReview articleمراجعة النظراء

3 اقتباسات (Scopus)


Immune-checkpoint inhibitors (ICIs) have revolutionized treatment of solid malignancies, leading in some cases to durable responses. However, an unchecked immune response might lead to mild to severe immune-related adverse events (irAEs). Pulmonary toxicity, though often referred to as Immune checkpoint inhibitor–related pneumonitis (ICI-pneumonitis), covers a broad and overlapping spectrum of pulmonary manifestations and has been described in < 10% of patients receiving ICI either alone or in combination. However, the actual numbers in real-world populations are high, and are likely to increase as the therapeutic indications for ICIs continue to expand to include other malignancies. Drug withdrawal is the mainstay of treatment for ICI-pneumonitis. However, a good number of patients with higher grades of toxicity may need corticosteroids. Patients with refractory disease need additional immunosuppressive agents. In this brief review, we succinctly discuss the incidence, risk factors, mechanisms, clinical and radiologic manifestations, diagnosis and summarize the current management strategies of ICI-pneumonitis.
اللغة الأصليةEnglish
الصفحات (من إلى)219-229
عدد الصفحات11
دوريةAdvances in Respiratory Medicine
مستوى الصوت90
رقم الإصدار3
المعرِّفات الرقمية للأشياء
حالة النشرPublished - يونيو 22 2022

ASJC Scopus subject areas

  • ???subjectarea.asjc.2700.2740???


أدرس بدقة موضوعات البحث “Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا